دورية أكاديمية

Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation.

التفاصيل البيبلوغرافية
العنوان: Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation.
المؤلفون: Lim JU; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Park S; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Yoon JH; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Lee SE; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Cho BS; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Kim YJ; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Lee S; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Kim HJ; Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea., Rhee CK; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. Electronic address: chinkook77@gmail.com.
المصدر: Respiratory medicine [Respir Med] 2023 Nov; Vol. 218, pp. 107410. Date of Electronic Publication: 2023 Sep 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 8908438 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3064 (Electronic) Linking ISSN: 09546111 NLM ISO Abbreviation: Respir Med Subsets: MEDLINE
أسماء مطبوعة: Publication: 2003- : Oxford : Elsevier
Original Publication: London : Baillière Tindall, in association with the British Thoracic Society, [c1989-
مواضيع طبية MeSH: Bronchiolitis Obliterans*/drug therapy , Bronchiolitis Obliterans*/etiology , Hematopoietic Stem Cell Transplantation*/adverse effects , Pulmonary Disease, Chronic Obstructive*, Humans ; Tiotropium Bromide/therapeutic use ; Budesonide/therapeutic use ; Retrospective Studies ; Budesonide, Formoterol Fumarate Drug Combination/therapeutic use ; Bronchodilator Agents
مستخلص: Background: Bronchiolitis obliterans syndrome (BOS) is the lung manifestation of chronic graft-versus-host disease after hematopoietic stem cell transplantation (HSCT). We assessed whether inhaled tiotropium add-on to the combination regimen including budesonide/formoterol improve pulmonary function and the chronic obstructive pulmonary disease assessment test (CAT) scores in patients with BOS.
Methods: Post-HSCT patients diagnosed as BOS in Seoul St. Mary's Hospital were reviewed retrospectively. Patients defined as BOS and treated with budesonide/formoterol/tiotropium combination therapy after budesonide/formoterol therapy from January 2011 to June 2019 were enrolled.
Results: Total of 86 patients were evaluated. After tiotropium add-on, the absolute FEV1 increased significantly from 1.47 ± 0.49 to 1.53 ± 0.57 L (p = 0.023) and the % predicted FEV1 from 45.0 ± 12.8 to 46.8 ± 14.5% (p = 0.031). The % predicted DLCO increased significantly after tiotropium add-on (from 61.6 ± 16.7 to 64.3 ± 16.3%, p = 0.028). Among 56 patients with complete CAT scores, no significant change was present in total CAT scores. In all, 30 of the 72 patients (41.7%) evidenced FEV1 increases > 100 mL, and 20 of 56 patients (35.7%) had CAT score decreases of ≥ 2 points. When the FEV1 and CAT scores were combined, the overall response rate to tiotropium add-on was 56.2% (41/73). The response group evidenced a significantly greater FVC increase, and a significant decrease in the RV/TLC ratio compared to the no-response group.
Conclusions: Inhaled tiotropium add-on to combination budesonide/formoterol significantly improved lung function, but not respiratory symptoms, in patients with post-HSCT BOS.
Competing Interests: Declaration of competing interest CK Rhee received consulting/lecture fees from MSD, AstraZeneca, GSK, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, Sanofi, and Bayer. All other authors also do not have competing interest.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
فهرسة مساهمة: Keywords: Bronchiolitis obliterans syndrome; Chronic graft-versus-host disease; Hematopoietic stem cell transplantation; Lung; Tiotropium
المشرفين على المادة: XX112XZP0J (Tiotropium Bromide)
51333-22-3 (Budesonide)
0 (Budesonide, Formoterol Fumarate Drug Combination)
0 (Bronchodilator Agents)
تواريخ الأحداث: Date Created: 20230911 Date Completed: 20231103 Latest Revision: 20231114
رمز التحديث: 20240628
DOI: 10.1016/j.rmed.2023.107410
PMID: 37696312
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-3064
DOI:10.1016/j.rmed.2023.107410